Cargando…

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance

BACKGROUND/AIMS: Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in patients with UC in Japan. We present an interim rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Shiro, Asano, Teita, Tsuchiya, Hiroaki, Sugimoto, Kanami, Imai, Yuya, Yokoyama, Seiji, Suzuki, Yasuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344245/ https://www.ncbi.nlm.nih.gov/pubmed/34333910 http://dx.doi.org/10.5217/ir.2021.00032

Ejemplares similares

Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan
por: Nakamura, Shiro, et al.
Publicado: (2022)

Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan
por: Yokoyama, Seiji, et al.
Publicado: (2021)

Golimumab in unresponsive ulcerative colitis
por: Lippert, Elisabeth, et al.
Publicado: (2014)

Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014)

Golimumab in the treatment of ulcerative colitis
por: Cunningham, Georgina, et al.
Publicado: (2019)

Golimumab for the treatment of ulcerative colitis
por: Flamant, Mathurin, et al.
Publicado: (2017)

Early-Phase Partial Mayo Score following Golimumab Treatment Is Associated with Endoscopic Improvement at 1 Year in Ulcerative Colitis: A post hoc Analysis of PURSUIT-J Randomized Controlled Trial
por: Nagano, Katsumasa, et al.
Publicado: (2022)

Serum IL-13 Predicts Response to Golimumab in Bio-Naïve Ulcerative Colitis
por: Kinoshita, Naohiko, et al.
Publicado: (2022)

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
por: Pugliese, Daniela, et al.
Publicado: (2016)

Management of elderly ulcerative colitis in Japan
por: Higashiyama, Masaaki, et al.
Publicado: (2019)

Long-Term Efficacy and Safety of Golimumab for Ulcerative Colitis in a Pediatric Inflammatory Bowel Disease Center in Japan
por: Tokita, Kazuhide, et al.
Publicado: (2022)

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
por: Bosca-Watts, Marta Maia, et al.
Publicado: (2016)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
por: Yu, Jongwook, et al.
Publicado: (2022)

Correction to: Management of elderly ulcerative colitis in Japan
por: Higashiyama, Masaaki, et al.
Publicado: (2019)

Therapeutic Drug Monitoring of Golimumab for the Prediction of Long-Term Clinical Remission in Patients with Ulcerative Colitis
por: Tawa, Hideki, et al.
Publicado: (2022)

Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed
por: Nagano, Katsumasa, et al.
Publicado: (2023)

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan
por: Saida, Takahiko, et al.
Publicado: (2017)

Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
por: Iborra, Marisa, et al.
Publicado: (2020)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure
por: Bressler, Brian, et al.
Publicado: (2018)

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland
por: Perrig, Kathrin, et al.
Publicado: (2022)

Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2023)

Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)
por: Hibi, Toshifumi, et al.
Publicado: (2017)

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis
por: Rutgeerts, P., et al.
Publicado: (2015)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
por: Hoque, Sami, et al.
Publicado: (2020)

Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report
por: Alhalabi, Marouf M., et al.
Publicado: (2022)

Real-World Safety and Effectiveness of Golimumab in Rheumatic Diseases: Post-Marketing Surveillance in Korea
por: Kim, Hyeongyeong, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
por: Magro, Fernando, et al.
Publicado: (2019)

Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan
por: Hongo, Haruyuki, et al.
Publicado: (2021)

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year
por: Gibson, Peter R, et al.
Publicado: (2016)

Persistence and Safety of Golimumab in Elderly Patients with Rheumatoid Arthritis and Renal Dysfunction in a Real-World Setting
por: Yokoyama, Seiji, et al.
Publicado: (2022)

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
por: Kato, Hideki, et al.
Publicado: (2018)

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
por: Ito, Shuichi, et al.
Publicado: (2018)

Safety and Effectiveness of Letermovir in Allogenic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan
por: Hiraishi, Itaru, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rg2aijqiv5pqb0hqsumutl9fgj